Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Bone Marrow Transplantation Année : 2023

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).

Mutlu Arat
  • Fonction : Auteur
Frederic Baron
Didier Blaise
Eolia Brissot
Paul G. Richardson
  • Fonction : Auteur

Résumé

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). A new definition for diagnosis, and a severity grading system for SOS/VOD in adult patients, was reported a few years ago on behalf of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this work is to update knowledge regarding diagnosis and severity assessment of SOS/VOD in adult patients, and also its pathophysiology and treatment. In particular, we now propose to refine the previous classification and distinguish probable, clinical and proven SOS/VOD at diagnosis. We also provide an accurate definition of multiorgan dysfunction (MOD) for SOS/VOD severity grading based on Sequential Organ Failure Assessment (SOFA) score.

Dates et versions

hal-04490452 , version 1 (05-03-2024)

Identifiants

Citer

Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, et al.. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).. Bone Marrow Transplantation, 2023, Bone Marrow Transplant, ⟨10.1038/s41409-023-01992-8⟩. ⟨hal-04490452⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More